Expression profile of microrna-145 in urothelial bladder cancer

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorDIP, Nelson
dc.contributor.authorREIS, Sabrina T.
dc.contributor.authorSROUGI, Miguel
dc.contributor.authorDALL'OGLIO, Marcos F.
dc.contributor.authorLEITE, Katia R. M.
dc.date.accessioned2014-01-28T22:16:07Z
dc.date.available2014-01-28T22:16:07Z
dc.date.issued2013
dc.description.abstractPurpose: Bladder cancer (BC) is the second most common malignancy of the urinary tract, with high mortality. The knowledge of the molecular pathways associated with BC carcinogenesis is crucial to identify new diagnostic and prognostic biomarkers. MicroRNAs (miRNAs) are short non-coding RNA molecules that play important roles in the regulation of gene expression by acting directly on mRNAs. miR-145 has been considered as a tumor suppressor, which targets the c-MYC, MUC-1 and FSCN1 genes. Our aim was to evaluate the expression profile of miR-145 in low-grade non-invasive and high-grade invasive bladder urothelial carcinomas. Materials and Methods: We studied 30 specimens of low-grade, non-invasive pTa and 30 of pT2/pT3 high-grade invasive UC obtained by transurethral resection or radical cystectomy, followed over a mean time of 16.1 months. Normal controls were represented by five samples of normal bladder biopsy from patients who underwent retropubic prostatectomy to treat BPH. miRNA extraction and cDNA generation were performed using commercial kits. Analysis was performed by qRT-PCR, and miR-145 expression was calculated using the 2-(Delta Delta ct) method; we used RNU-43 and RNU-48 as endogenous controls. Results: miR-145 was under-expressed in 73.3% and 86.7% of pTa and pT2/pT3, respectively, with expression means of 1.61 for the former and 0.66 for the last. There were no significant differences in miR-145 expression and histological grade, tumor stage, angiolymphatic neoplastic invasion and tumor recurrence. Conclusion: miR-145 is under-expressed in low-grade, non-invasive and high-grade invasive urothelial bladder carcinoma and may play an important role in the carcinogenesis pathway, being an interesting candidate diagnostic marker.
dc.description.indexMEDLINE
dc.description.sponsorshipFAPESP [10/50824-1]
dc.identifier.citationINTERNATIONAL BRAZ J UROL, v.39, n.1, p.95-101, 2013
dc.identifier.doi10.1590/S1677-5538.IBJU.2013.01.12
dc.identifier.issn1677-5538
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/3870
dc.language.isoeng
dc.publisherBRAZILIAN SOC UROL
dc.relation.ispartofInternational Braz J Urol
dc.rightsopenAccess
dc.rights.holderCopyright BRAZILIAN SOC UROL
dc.subjectMicroRNAs
dc.subjectMIRN145 microRNA, human [Supplementary Concept]
dc.subjectUrinary Bladder
dc.subjectDiagnostic Techniques, Urological
dc.subjectBiological Markers
dc.subject.othercell-carcinoma
dc.subject.othergene-mutations
dc.subject.otherpathways
dc.subject.othertargets
dc.subject.othergrowth
dc.subject.othermir-145
dc.subject.otherfgfr3
dc.subject.otherp53
dc.subject.othermirnas
dc.subject.otherfamily
dc.subject.wosUrology & Nephrology
dc.titleExpression profile of microrna-145 in urothelial bladder cancer
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcNELSON GASPAR DIP JUNIOR
hcfmusp.contributor.author-fmusphcSABRINA THALITA DOS REIS FARIA
hcfmusp.contributor.author-fmusphcMIGUEL SROUGI
hcfmusp.contributor.author-fmusphcMARCOS FRANCISCO DALL'OGLIO
hcfmusp.contributor.author-fmusphcKATIA RAMOS MOREIRA LEITE
hcfmusp.description.beginpage95
hcfmusp.description.endpage101
hcfmusp.description.issue1
hcfmusp.description.volume39
hcfmusp.origemWOS
hcfmusp.origem.pubmed23489501
hcfmusp.origem.scieloSCIELO:S1677-55382013000100095
hcfmusp.origem.scopus2-s2.0-84878453399
hcfmusp.origem.wosWOS:000323495800014
hcfmusp.publisher.cityRIO DE JANEIRO
hcfmusp.publisher.countryBRAZIL
hcfmusp.relation.referenceAmbros V, 2003, CELL, V114, P269, DOI 10.1016/S0092-8674(03)00562-2
hcfmusp.relation.referenceAmbros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8
hcfmusp.relation.referenceBakkar AA, 2003, CANCER RES, V63, P8108
hcfmusp.relation.referenceBartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
hcfmusp.relation.referenceBlenkiron C, 2007, HUM MOL GENET, V16, pR106, DOI 10.1093/hmg/ddm056
hcfmusp.relation.referenceBorden LS, 2005, CURR OPIN ONCOL, V17, P275, DOI 10.1097/01.cco.0000156985.47984.9e
hcfmusp.relation.referenceCastillo-Martin M, 2010, UROL ONCOL-SEMIN ORI, V28, P401, DOI 10.1016/j.urolonc.2009.04.019
hcfmusp.relation.referenceCatto JWF, 2009, CANCER RES, V69, P8472, DOI 10.1158/0008-5472.CAN-09-0744
hcfmusp.relation.referenceChiyomaru T, 2010, BRIT J CANCER, V102, P883, DOI 10.1038/sj.bjc.6605570
hcfmusp.relation.referenceCimmino A, 2006, P NATL ACAD SCI USA, V103, P2464, DOI 10.1073/pnas.0510793103
hcfmusp.relation.referenceCimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
hcfmusp.relation.referenceCroce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036
hcfmusp.relation.referenceIchimi T, 2009, INT J CANCER, V125, P345, DOI 10.1002/ijc.24390
hcfmusp.relation.referenceIzzotti A, 2009, FASEB J, V23, P806, DOI 10.1096/fj.08-121384
hcfmusp.relation.referenceJebar AH, 2005, ONCOGENE, V24, P5218, DOI 10.1038/sj.onc.1208705
hcfmusp.relation.referenceJemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
hcfmusp.relation.referenceJemal A, 2011, CA CANC J CLIN, V61, P134
hcfmusp.relation.referenceJohnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
hcfmusp.relation.referenceLewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
hcfmusp.relation.referenceLin TX, 2009, J UROLOGY, V181, P1372, DOI 10.1016/j.juro.2008.10.149
hcfmusp.relation.referenceMcConkey DJ, 2010, UROL ONCOL-SEMIN ORI, V28, P429, DOI 10.1016/j.urolonc.2010.04.008
hcfmusp.relation.referenceMichael MZ, 2003, MOL CANCER RES, V1, P882
hcfmusp.relation.referenceOrnitz DM, 1996, J BIOL CHEM, V271, P15292
hcfmusp.relation.referenceOzen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809
hcfmusp.relation.referencePandith AA, 2010, UROL ONCOL, V3
hcfmusp.relation.referenceSachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106
hcfmusp.relation.referenceSachdeva M, 2010, AM J TRANSL RES, V2, P170
hcfmusp.relation.referenceShi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200
hcfmusp.relation.referenceSpizzo R, 2010, CELL DEATH DIFFER, V17, P246, DOI 10.1038/cdd.2009.117
hcfmusp.relation.referenceSuzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199
hcfmusp.relation.referencevan Rhijn BSW, 2004, CANCER RES, V64, P1911, DOI 10.1158/0008-5472.CAN-03-2421
hcfmusp.relation.referenceVignjevic D, 2006, J CELL BIOL, V174, P863, DOI 10.1083/jcb.200603013
hcfmusp.relation.referenceWu XR, 2009, CANCER METAST REV, V28, P281, DOI 10.1007/s10555-009-9189-4
hcfmusp.remissive.sponsorshipFAPESP
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication7b98028d-1464-41f7-b473-7326a36a8d3c
relation.isAuthorOfPublication73be4bca-f8ad-443f-90b5-10e2e62b1e27
relation.isAuthorOfPublicationcff561dd-5732-4af5-abe9-538da0cdf4d2
relation.isAuthorOfPublication0349f82a-1538-4caa-908f-f81634bd6256
relation.isAuthorOfPublication23772d3b-0da7-472f-8d56-e6312dbf95c1
relation.isAuthorOfPublication.latestForDiscovery7b98028d-1464-41f7-b473-7326a36a8d3c
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_DIP_Expression_profile_of_microrna_145_in_urothelial_bladder_2013.PDF
Tamanho:
211.55 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/55